Program

The ANZCHOG ASM 2025 program will include plenary sessions, invited speaker sessions, industry involvement and concurrent paper sessions.

Please find below a preliminary copy of the 2025 ASM program as a guide of what to expect. Please note the program is subject to changes.  

The ASM program will now start on Wednesday afternoon, 30 July 2025 and conclude on Friday night, 1 August 2025

 Time
0800-0900
Registration open
Arrival tea and coffee
0900-1500
ANZCHOG Pre-Conference Nurses Workshop
ANZCHOG Pre-Conference Allied Health Workshop: Multidisciplinary Collaboration for Optimal Patient Outcomes
ANZCHOG Paediatric Oncology Fellows Day
(Offsite)
Made possible by Cure Brain Cancer Foundation
Made possible by MY Room
Made possible by Day One Biopharmaceuticals
1500-1600
Afternoon Tea – Registration Open, Trade Display and Poster Viewing
1600-1630
Opening Ceremony
1630-1715
Plenary 1

Can we cure all children of cancer without harm?
Dr Quentin Campbell-Hewson, RVI Newcastle-upon-Tyne, UK
1715-1800
Plenary 2 – TBC
1800-1915
1930-2130
Partner Dinner Symposium
How is the profile of patients with hepatic VOD evolving in line with the treatment landscape?
Prof. Selim Corbacioglu, University of Regensburg

Sponsored by Jazz Pharmaceuticals
Key for Program
Time
0730-0830
.partnership-50-2025
0800-0900
.break-50-2025
1345-1515
.subheader2025
[Placeholder]
Time
0730-0830
Breakfast Symposium 1
Sponsored by Amgen
0800-0900
Registration open
Arrival tea and coffee
0900-0945
Plenary 3

TBC
Prof Robert Wynn
0945-1030
Plenary 4

Network neuroscience and brain repair in children with pediatric brain tumours.
Dr Donald Mabbott, SickKids
Involvement made possible by Robert Connor Dawes Foundation
1030-1100
Morning Tea – Trade Display and Poster Viewing
1100-1145
Plenary 5

Approaches to relapse/refractory high-risk neuroblastoma
Dr Daniel Morgenstern, SickKids
Involvement made possible by Norgine
1145-1230
Plenary 6
A/ Prof Peter Grimison, Chris O’Brien Lifehouse
Involvement made possible by Youth Cancer Service
1230-1345
Lunch – Trade Display and Poster Viewing
Partner Lunch Symposium
Sponsored by Alexion
1345-1515
ANZCHOG Clinical Trials Update
1515-1545
Afternoon Tea – Trade Display and Poster Viewing
1545-1615
Meet the Expert Session 1
Meet the Expert Session 2
Meet the Expert Session 3
Brought to you by Recordati Rare Diseases
1630-1815
Concurrent 1 – Neuro-Oncology
Concurrent 2 – Adolescent and Young Adult
Concurrent 3 – Optimising Patient Experience
Driving CARs into DMG
Prof David Ziegler, Sydney Children’s Hospital
Involvement made possible by RUNDIPG
P3BeP
A/Prof Peter Grimison, Chris O’Brien Lifehouse
Involvement made possible by Youth Cancer Service
Can we go home now?
QPPHON enables care as close to home as possible
Ms Jessica Nicholson, Children’s Health Queensland
A Review of the Diagnosis, Treatment and Outcomes for Adolescents and Young Adults with Gonadal Germ Cell Tumours in Queensland from 2017 to 2022
Dr Rick Walker, Queensland Children’s Hospital
Improving the child cancer experience for New Zealand families: A qualitative study
Dr Anna Timmings, Te Whatu Ora – Lakes
Presentation TBC
Dr Donald Mabbott, SickKids
Involvement made possible by Robert Connor Dawes Foundation
Enhancing Australian AYA Psychosocial Care: Updated Guidelines and State of the Literature
A/ Prof Ursula Sansom-Daly, University of New South Wales
Top Ten Research Priorities for Cancer in Children and Young People in Australia
Mrs Gayani De Silva, Queensland University of Technology
Evaluating Distress Scores and Unmet Needs in Adolescents and Young Adults with Cancer Undergoing Treatment or as Survivors in a Large Australian Paediatric and Adult Health Service
Miss Tegan Dunmall, Monash Health
Collaborating for Change: Advancing Global Health Research with SIOP Oceania
Dr Trisha Soosay Raj, Queensland Health
DNA Damage Response Inhibitors Enhance the Efficacy of Radiation in Preclinical Models of Medulloblastoma
Dr Meegan Howlett, The Kids Institute Australia
Optimising Intravenous Nutrition in Paediatric Cancer Care: Insights from New Zealand’s Leading Tertiary Centre
Dr Amy Lovell, The University of Auckland and Starship Blood and Cancer Centre
Building resilience: Workforce strategies to combat distress and burnout in Australian children’s cancer nurses
Prof Natalie Bradford, Queensland University of Technology
Radiological, Histopathological and Molecular Features of Gliomas in Li Fraumeni Syndrome
Miss Noemi Fuentes Bolano, Sydney Children’s Hospital and Children’s Cancer Institute
mTKIs in Sarcoma – The Story So Far
Dr Quentin Campbell-Hewson, RVI Newcastle-upon-Tyne, UK
What do First Nations Communities Need From Childhood Cancer Research?
Dr Jessica Buck, The Kids Research Institute
Launch of the Australian Family Handbook for Childhood Brain Tumour
Ms Melanie Rolfe, Queensland University of Technology
Prioritising equitable outcomes for children and young people with cancer: Using the He Pikinga Wairoa Implementation Framework to co-design a prehabilitation intervention in Aotearoa, New Zealand
Miss Alexis Ross, University of Auckland
1815-1915
Time
0730-0830
.partnership-50-2025
0800-0900
.break-50-2025
1345-1515
.subheader2025
[Placeholder]
Key for Program
Time
0730-0830
Breakfast Symposium 2
Sponsored by Bayer
0800-0900
Registration open
Arrival tea and coffee
0900-0945
Plenary 7

Curative Treatment Options for Thalassemia and Sickle Cell Disease in 2025
Prof Selim Corbacioglu, University of Regensburg
Involvement made possible by Jazz Pharmaceuticals

0945-1030
Plenary 8

TBC
Prof Lee Dupuis, SickKids
1030-1100
Morning Tea – Trade Display and Poster Viewing
1100-1230
Concurrent 4 – Precision Medicine
Concurrent 5 – Equitable World Health
Concurrent 6 – Haematology
Mapping Proteomic Differences between High-Risk and Non-High-Risk Neuroblastoma
Miss Urwah Nawaz, Children’s Medical Research Institute
Strengthening Paediatric Cancer and Palliative Care Capacity in Papua New Guinea
Dr Gwenda Anga, Port Moresby General Hospital
Involvement made possible by QUT Palliative Care
Inborn errors of immunity in the Haematology clinic.
Dr Peter McNaughton, Queensland Children’s Hospital
Quality of life, distress and support needs of families of children with high-risk sarcoma enrolled in a precision medicine trial
Dr Brittany McGill, University New South Wales
Approach to Philadelphia-Negative Myeloproliferative Neoplasms in Children
Dr Denitza Mironova, Perth Children’s Hospital
The STAMP Inhibitor asciminib is a Novel Therapy for ABL1-rearranged ALL
Dr Laura Eadie, South Australian Health and Medical Research Institute
What’s new in Sickle cell disease ?
Dr Anthea Greenway, Royal Children’s Hospital Melbourne
Thematic analysis of the key factors that guide oncologist decisions to use precision-guided treatment in paediatric cancer
Miss Xian Zou, University New South Wales
Current Incidence And Outcome Of Childhood Cancer In Fiji: A Baseline For The Global Initiative For Childhood Cancer
Dr Siobhan Cross, Health NZ
Expanding the Aplastic Anaemia and Other Bone Marrow Failure Registry (AAR) to New Zealand – Exploring epidemiology, availability of diagnostic testing, and genomic profiles
Dr Nathanael Lucas, Monash University and The University of Otago
PREDICT and Validate: Decoding the Genome of Childhood Cancer Predisposition
Miss Safaa Al Haj Hussein, Children’s Hospital at Westmead
Childhood Cancer Survival in Australia: A population-based analysis of prognostic indicators and survival disparities by geography and socio-economic status
Prof Natalie Bradford, Queensland University of Technology
What Should We Research? Defining Priorities for Paediatric Haematopoietic Stem Cell Transplant (HSCT) Through Stakeholder Engagement
Ms Roxanne Dyas, Murdoch Childrens Research Institute
Derivation of a Proteomic Signature for Prediction of Relapse in Paediatric Acute Lymphoblastic Leukaemia
Dr Veronica Yeung, Children’s Medical Research Institute
Quantifying the social and economic burden of childhood cancer on New Zealand families and the impact of location, ethnicity and cancer type
Dr Anna Timmings, Te Whatu Ora – Lakes
1230-1345
Lunch – Trade Display and Poster Viewing
Partner Lunch Symposium
Sponsored by Norgine
1345-1530
Concurrent 7 – Solid Tumours
Concurrent 8 – Supportive Cares and Treatments
Concurrent 9 – Leukaemia/ Lymphoma
SMARCB1 and rhabdoid tumours: germline versus acquired pathogenic variants
Miss Noemi Fuentes Bolano, Sydney Children’s Hospital and Children’s Cancer Institute
Antibiotic-Induced Ablation of Gut Microbiota in Murine Models of Acute Lymphoblastic Leukaemia Results in Variable Patterns of Leukaemic Cell Engraftment
Ms Cate Cheney, South Australian Health and Medical Research Institute
Variations of rotationplasty surgical techniques and implications for physiotherapy in four children at the Queensland Children’s Hospital
Ms Elise Mosey, Children’s Health Queensland
Elevated plasma CXCL9 and CHI3L1 prior to haematopoietic stem cell transplant predict post transplant lung complications in children
Dr Hannah Walker, The Royal Children’s Hospital
Addressing caregiver unmet information needs at end-of treatment for acute lymphoblastic leukaemia: The Emerge Program
Dr Cinzia De Luca, Children’s Cancer Centre
New combinations for HR-NB through systematic drug screening and rational targeting of relapse pathways in clinical trial-like PDX studies
Mr Brandon Hearn, Children’s Cancer Institute
Pharmacogenomics in Paediatric Oncology: Australian Patient and Caregiver Perspectives
Ms Claire Moore, Murdoch Children’s Research Institute
Next generation sequencing (NGS) for detection and monitoring of minimal residual disease in acute lymphoblastic leukaemia
Dr Nicola Mason, The Children’s Hospital at Westmead
Defining mechanisms of cisplatin resistance in osteosarcoma using a whole genome CRISPR activation screen
Dr Elise Young, Monash Health and Hudson Institute
Y-Site Compatibility of Ketamine with Other Commonly Administered Drugs in Pediatric Oncology
Mr Johnathan Soggee, Perth Children’s Hospital
Innovative Approach to Physiotherapy Management of Children with Respiratory Complications of Haematopoietic Stem Cell Transplant
Ms Joanne Leavitt, Queensland Children’s Hospital
Journey mapping of paediatric patients with orthopaedic sarcoma: challenges and support needs identified
Mrs Caitlin Smith, Perth Children’s Hospital
Clinical characterisation and early intervention for the physically vulnerable child with cancer: protocol for a mixed-methods pilot RCT
Dr Sarah Grimshaw, Murdoch Children’s Research Institute
Acquired copy number variants are highly correlated with Ph+ALL subgroups identified by transcriptomic analysis
Dr Jacqueline Rehn, South Australian Health and Medical Research Institute
Identification of molecular prognostic and therapy resistance signatures in childhood and AYA osteosarcomas
Dr Nataliya Zhukova, Hudson Institute of Medical Research
A Surveillance Study in Multi-Organ Cancer Predisposition Syndromes in Paediatrics (SMOC Junior): Preliminary Results
Dr Noemi Fuentes Bolanos, Sydney Children’s Hospital and Children’s Cancer Institute
Body Composition Changes in Early Survivors of Childhood Brain Tumours: Data from the CARaB C Study
Dr Erin Sharwood, Children’s Health Queensland
1530-1600
Afternoon Tea – Trade Display and Poster Viewing
1600-1645
Plenary 9

Emerging therapies in inherited bleeding disorders
Dr Jane Mason, Royal Brisbane and Women’s Hospital
1645-1800
ANZCHOG 2025 ASM Best Abstracts

Queensland Youth Cancer Service: Prioritising Adolescent and Young Adult futures through connection and wrap around care
Mrs Tracy Till, Queensland Children’s Hospital

Potential for Pharmacogenomics to Improve Medication Safety and Efficacy in Australian Paediatric Oncology Patients
Ms Claire Moore, Murdoch Children’s Research Institute

Using Methylation Array Profiling for Juvenile Myelomonocytic Leukaemia Classification
Dr Christine White, Victorian Clinical Genetics Services

Exploring Symptom Burden and Symptom Clusters in Childhood and Adolescent Cancer Survivors: A Multi-perspective Cross-sectional Study
Dr Sarah Ellis, University New South Wales

Towards a National System for Minimally Invasive Monitoring of any Childhood Cancer: Lessons Learnt and Opportunities for Impact
Mr Rob Salomon, Children’s Cancer Institute
1900-0000
Venue: Brisbane City Hall
Dress code: Cocktail
Information: An elegant evening of celebration featuring a three course dinner, drinks, and the abstract awards. Set in one of the city’s most iconic venues, this special night offers the perfect opportunity to connect with colleagues and honour excellence in our field.
Key for Program
Time
0730-0830
.partnership-50-2025
0800-0900
.break-50-2025
1345-1515
.subheader2025
[Placeholder]

Key dates